Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
The mRNA vaccines for SARS-CoV-2 have demonstrated efficacy and immunogenicity in the real-world setting. However, most of the research on vaccine immunogenicity has been centered on characterizing the antibody response, with limited exploration into the persistence of spike-specific memory B cells. Here we monitored the durability of the memory B cell response up to 9 months post-vaccination, and characterized the trajectory of spike-specific B cell phenotypes in healthy individuals who received two doses of the BNT162b2 vaccine. To profile the spike-specific B cell response, we applied the tSNE and Cytotree automated approaches. Spike-specific IgA+ and IgG+ plasmablasts and IgA+ activated cells were observed 7 days after the second dose and disappeared 3 months later, while subsets of spike-specific IgG+ resting memory B cells became predominant 9 months after vaccination, and they were capable of differentiating into spike-specific IgG secreting cells when restimulated in vitro. Other subsets of spike-specific B cells, such as IgM+ or unswitched IgM+IgD+ or IgG+ double negative/atypical cells, were also elicited by the BNT162b2 vaccine and persisted up to month 9. The analysis of circulating spike-specific IgG, IgA, and IgM was in line with the plasmablasts observed. The longitudinal analysis of the antigen-specific B cell response elicited by mRNA-based vaccines provides valuable insights into our understanding of the immunogenicity of this novel vaccine platform destined for future widespread use, and it can help in guiding future decisions and vaccination schedules.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine
- Date Crossref
- 23/06/2023
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Siena Laboratory of Molecular Microbiology and Biotechnology pays non établi dans la noticeUniversité ou école supérieure
-
LUM Jean Monnet University pays non établi dans la noticeUniversité ou école supérieure
-
LUM University “Giuseppe Degennaro” Department of Medicine and Surgery pays non établi dans la noticeUniversité ou école supérieure
-
LUM University "Giuseppe Degennaro" Department of Medicine and Surgery pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital of Siena Department of Medical Sciences pays non établi dans la noticeUniversité ou école supérieure
Laboratory of Molecular Microbiology and Biotechnology — University of Siena, LUM Jean Monnet University et Department of Medicine and Surgery — LUM University “Giuseppe Degennaro”, avec 2 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.